Theranos: The Governance Failures Investors Overlooked

Theranos promised to transform healthcare with technology that could run many blood tests from a few drops of blood. Founded by Elizabeth Holmes in 2003, it reached a valuation of around $9 billion, formed a major partnership with Walgreens and assembled a board of famous names. By 2018 it had collapsed, and Holmes and former president Ramesh "Sunny" Balwani were later convicted of fraud.

Theranos is often told as a story about one founder's deception. It is also a story about governance and due diligence failures that allowed that deception to continue for years. This post-mortem focuses on what investors, boards and partners missed.

1. What Happened

• Theranos claimed its devices could run a wide range of tests from a finger-prick sample.
• In reality, the technology did not work as claimed, and the company ran many tests on modified third-party equipment.
• In 2015, investigative reporting by The Wall Street Journal exposed the problems.
• Regulators sanctioned the company, the SEC charged Holmes and Balwani with fraud in 2018, and the company dissolved later that year.
• Holmes was convicted in 2022 of defrauding investors and sentenced to more than 11 years in prison; Balwani was convicted on all counts and received a longer sentence.

2. Governance Failures

A board without relevant expertise

Theranos's board included former cabinet secretaries, senior military figures and other prominent names, but few directors with deep expertise in laboratory medicine or diagnostics. They were poorly placed to evaluate the technology. See startup boards and governance.

Concentrated founder control

Holmes held voting control, limiting the ability of investors and directors to challenge decisions. See dual-class shares.

Secrecy presented as strategy

The company cited trade secrets to avoid sharing data, peer-reviewed research or independent validation.

Silencing concerns

Employees who raised concerns faced aggressive legal pressure, and whistleblowers were critical to exposing the fraud.

3. Due Diligence Failures

• No independent technical validation. Many investors did not require experts to test the technology or review data.
• Reliance on reputation. Prominent board members and partners were taken as proxies for quality.
• Investor profile. Several major investors were family offices and individuals without specialist healthcare diligence teams, while some experienced healthcare investors reportedly passed.
• Partner assumptions. Large commercial partners moved forward without fully verifying performance.
• Fear of missing out on a high-profile, fast-rising company.

4. Lessons for Investors

• Demand independent validation of core technology, especially in regulated fields such as healthcare. See medtech funding and FDA timelines.
• Check board expertise, not just board prominence.
• Treat secrecy as a risk, not a feature, when it prevents basic verification.
• Run thorough reference checks, including former employees. See founder reference checks.
• Protect information rights and governance terms that allow investors to see what is happening. See information rights.
• Recognise that specialist investors passing can be a meaningful signal.

For science-driven sectors, see also separating science from hype in longevity startups.

Frequently Asked Questions

How much was Theranos worth?

At its peak, around $9 billion, based on private funding rounds.

Why did the board not detect the fraud?

Many directors lacked relevant scientific and medical expertise, and the company limited access to information.

Who invested in Theranos?

Largely family offices and wealthy individuals, along with some funds, many without specialist healthcare diligence capabilities.

What happened to Elizabeth Holmes?

She was convicted in 2022 of defrauding investors and sentenced to more than 11 years in prison.

The Bottom Line

Theranos was a fraud, but it was enabled by weak governance, a board without relevant expertise, concentrated founder control and investors who relied on reputation instead of verification. The lessons apply to every investor in technology-driven companies: validate independently, insist on real governance and treat secrecy as a warning sign.

Global Capital Network connects investors with vetted opportunities through our events and investor network. Get in touch to learn more.

This article is general information, not investment or legal advice.